Jam

Ascent Solar Technologies is offering 1,000,000 shares of common stock or pre-funded warrants, alongside warrants for another 1,000,000 shares, priced at $2.00 per share. The offering, led by H.C. Wainwright & Co., aims to raise $2 million, with an anticipated close by June 30, 2025. Proceeds will fund working capital, product development, and general expenses. The company’s focus is on high-performance flexible solar panels for various applications.

Shell plc announced the repurchase of a significant number of its own shares on June 27, 2025, as part of its capital management strategy. The announcement details the aggregated share repurchase transactions, including the number of shares purchased, prices paid, venue, and currency. This is part of a buy-back program initiated in May 2025.

Biogen released positive new data on its SMA treatment, SPINRAZA (nusinersen). Findings from the DEVOTE and NURTURE trials highlight the drug’s continued efficacy. The DEVOTE data suggests potential benefits from a higher dose regimen for previously treated patients, showing functional improvements across different patient groups. The final NURTURE study results reinforce the value of early intervention, demonstrating long-term benefits and safety. Biogen is awaiting regulatory approvals for the new higher dose regimen.

OFA Group (Nasdaq: OFAL) plans to acquire a 60% stake in Aspire Homes Realty and RateDNA, a real estate and lending platform, to expand its revenue streams. This strategic move aims to leverage the acquired team’s expertise and drive growth in residential real estate and specialty lending markets. The acquisition, expected to offer integrated services and investor-focused mortgage products, is subject to risks outlined in forward-looking statements.

IDEAYA Biosciences announced stock option grants to a new employee. The company awarded 95,600 shares at $22.29 per share under its 2023 plan, aiming to attract talent. Options vest over four years, with 25% vesting after the first year. IDEAYA, a precision medicine oncology company, focuses on targeted therapies based on molecular diagnostics and synthetic lethality approaches.

TotalEnergies acquires Moeve’s 25% stake in Suriname’s Block 53, partnering with APA and Petronas. Strategically located near Block 58 and the Baja-1 discovery, the move aims to unlock new resources for the GranMorgu project, leveraging infrastructure for further development and solidifying TotalEnergies’ position in the region’s deepwater oil and gas sector. Javier Rielo emphasizes expanded production potential.

Endeavour Mining announced a share buyback on June 27, 2025, purchasing 1,000 shares from Stifel Nicolaus Europe Limited on June 26, 2025, at a price of 2,250.00 GBp per share. This action, part of a previously announced buyback program, reflects the company’s commitment to shareholder value and optimizing its capital structure. Following this, the company will have 241,854,962 ordinary shares in issue.

Achieve Life Sciences priced a public offering of common stock and warrants at $3.00 per share to fund its cytisinicline program, targeting nicotine dependence. The offering, expected to close around June 30, 2025, aims to raise approximately $45 million, which will be used to advance cytisinicline through the FDA approval process. Cytisinicline, with Breakthrough Therapy designation, is designed to interact with nicotine receptors, potentially aiding smoking cessation.

Ecopetrol S.A. is contesting a COP 1.0 trillion tax assessment related to gasoline imports in Colombia, with an additional COP 2.1 trillion in estimated interest. The Tax Authority demands corrections to customs declarations between 2022-2024. The refinery is challenging the assessment and has been paying VAT on gasoline/diesel imports since January 2025, while maintaining its right to challenge the interpretation. The company, a major energy player, also highlights its international presence and commitment to compliance.

Sage Potash Corp. closed a non-brokered private placement, raising C$6 million, exceeding its initial C$4 million target. The financing will accelerate field activity, planning, and permitting for its Utah potash project. The offering involved 24 million units and warrants. Proceeds will also fund exploration, infrastructure planning, and working capital. Securities are subject to a hold period, and the TSX Venture Exchange granted conditional approval.